Compare Cadence Design Systems Inc (CDNS) vs Charles River Laboratories Intl. Inc (CRL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cadence Design Systems Inc vs Charles River Laboratories Intl. Inc — how do they compare? Cadence Design Systems Inc trades at $326.19 (market cap $90.20B), while Charles River Laboratories Intl. Inc trades at $284.99 (market cap $13.46B). The key difference: Cadence Design Systems Inc is far larger — about 6.7× Charles River Laboratories Intl. Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Cadence Design Systems Inc nearer its low. Which is the better fit depends on your goals.
| CDNS | CRL | |
|---|---|---|
Market Cap | $90.20B | $13.46B |
Sector | Technology | Health |
52-Week High | $416.39 | $282.00 |
52-Week Low | $265.66 | $145.57 |
Enterprise Value | $91.41B | $16.30B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cadence Design Systems (CDNS) trades at $331.91, down 2.16% amid a bearish technical signal, though it remains supported by strong fundamentals. The company reported Q2 2026 earnings that beat estimates, with revenue growth of 24.2% driven by AI demand, and raised its full-year outlook. Analyst consensus is strongly bullish with an average price target of $415.11, representing 25% upside potential from current levels.
The stock offers compelling growth prospects from AI-driven semiconductor design demand, with record backlog of $8.1 billion supporting future revenue visibility. Key risks include high valuation multiples (P/E 65.12) and potential semiconductor cycle volatility. Institutional ownership remains strong with recent position increases by major funds like Amundi.
Charles River Laboratories (CRL) trades at $277.00, up 3.56% on the day and near its 52-week high of $277.07, reflecting strong bullish momentum. The stock exhibits positive technical signals with moving averages indicating an uptrend, though oscillators suggest overbought conditions. Fundamentally, the company reported Q2 2026 EPS of $3.02, beating estimates, and raised full-year guidance, yet faces profitability challenges with a negative net income margin of -5.96% and elevated valuation ratios like a P/E of 684.85. Recent news highlights improved biotech demand and institutional buying interest.
The outlook for CRL is cautiously optimistic, driven by earnings beats and raised guidance, but high valuation and weak profitability pose risks. Investment opportunity lies in sustained demand for drug development services, while risks include margin pressure, debt levels, and sensitivity to biotech funding cycles. The stock's proximity to all-time highs warrants monitoring for pullbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cadence Design Systems Inc
Cadence Design Systems is a provider of electronic design automation software, intellectual property, and system design and analysis products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. Cadence offers a portfolio of design IP, as well as system design and analysis products, which enable system-level analysis and verification solutions. Cadence's comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers, alongside secular digitalization of various end markets, benefits EDA vendors like Cadence.
Read more on CDNS →About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →
